Fresh Tracks Therapeutics Reports Positive Topline Results from Phase 1 Study

(24/7 MARKET NEWS) – Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) announced, after yesterday’s market close, positive topline results from the single ascending dose and multiple ascending dose parts of its Phase 1 clinical trial evaluating FRTX-02 in healthy subjects. FRTX-02 is an orally bioavailable potential first-in-class DYRK1A inhibitor that aims to restore immune balance and the Company’s Board of Directors approved an exploratory process to evaluate strategic options to progress the development of its novel pipeline.

Fresh Tracks is at $2.72, up $0.89 (+48.63%), on 720 thousand premarket shares.

Its 52-week trading range is $1.30 to $18.945. It’s now trading at levels last seen in August and, if it can break through its resistance around the $3 level on strong volume, its key resistance levels are around the $4 and $6  levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.